EUPRAXIA PHARMACEUTICALS INC. EPRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | -$38.6M | — | — | $80.4M |
| 2024 | $0 | -$25.5M | — | — | $33.4M |
| 2023 | $0 | -$28.2M | — | — | $892,326 |
| 2022 | — | -$18.5M | — | — | $7.2M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0001581178 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.